The UAE is set to see increased manufacturing of generic drugs following the acquisition by a group of investors lead by French company Sanofi of a 66% equity stake in GlobalPharma from Dubai Investments.
GlobalPharma is being integrated as part of Sanofi to become the platform to manufacture and promote the generic drug portfolio of Sanofi in Middle East markets.
The portfolio will include, gastrointestinal drugs, anti infective agents and cardiovascular drugs. Globalpharma currently manufactures and markets drugs for 14 middle eastern markets. The combination of Global Pharma's market reach and Sanofi's industrial production technology and knowledge is expected to bring significant commercial advantages.